Rudolf A. de Boer
Uppsala University(SE)University Medical Center Groningen(NL)University of Groningen(NL)Erasmus MC(NL)Cardiovascular Institute Hospital(JP)ERN GUARD-Heart(NL)Oxford BioMedica (United Kingdom)(GB)Erasmus MC Cancer Institute(NL)Erasmus University Rotterdam(NL)
Publications by Year
Research Areas
Heart Failure Treatment and Management, Cardiovascular Function and Risk Factors, Diabetes Treatment and Management, Cardiomyopathy and Myosin Studies, Galectins and Cancer Biology
Most-Cited Works
- → 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure(2021)12,270 cited
- → Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction(2019)6,600 cited
- → 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)(2022)2,508 cited
- → Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction(2022)2,473 cited
- → 2023 ESC Guidelines for the management of cardiomyopathies(2023)2,116 cited
- → 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure(2023)1,935 cited